People with NSCLC with the CD74–ROS1 rearrangement have longer progression-free survival (PFS) and overall survival (OS) than those with other types of rearrangements (Li et al., 2018), but no similar conclusions have been found in other studies (Cui et al., 2020). This evidence concerns the gene CD74 and non-small cell lung carcinoma.